Award Number: DAMD17-00-1-0358

TITLE: Cloning and Characterization of Genes that Inhibit

TRAIL-Induced Apoptosis of Breast Cancer Cells

PRINCIPAL INVESTIGATOR: Hong-Bing Shu, Ph.D.

CONTRACTING ORGANIZATION: The National Jewish Medical

and Research Center Denver, Colorado 80206

REPORT DATE: April 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for information Operations and Reports, 1215 Jefferson Davis Highway, Sulte 1204, Arilington, VA 22202-4302, and to the Office of Management and Burdent, Paperwork Reduction Project (0704-0188). Washington, DC 20503

Management and Budget, Paperwork Reduction Proje	ct (0704-0188), Washington, DC 20503			
1. AGENCY USE ONLY	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED		
(Leave blank)	April 2003	Annual (1 Apr	02 - 31 Mar	93)
4. TIT LEAND SUBTITLE			5. FUNDING N	UMBERS
Cloning and Characterization of Genes that Inhibit			DAMD17-00-	-1-0358
TRAIL-Induced Apoptosis of Breast Cancer Cells				
6. AUTHOR(S)				
Hong-Bing Shu, Ph.D.				
•				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)				G ORGANIZATION
The National Jewish Medi	cal and Research Cent	er	REPORT NUI	MBER
Denver, Colorado 80206				
E-Mail: shuh@njc.org				
9. SPONSORING / MONITORING			40 0000000	
AGENCY NAME(S) AND ADDRESS(ES)				NG / MONITORING EPORT NUMBER
U.S. Army Medical Resear	ch and Materiel Comma	nd		
Fort Detrick, Maryland				
11. SUPPLEMENTARY NOTES				
		•		
12a. DISTRIBUTION / AVAILABILITY S				12b. DISTRIBUTION CODE
Approved for Public Rele	age: Distribution IInl	imited		

13. ABSTRACT (Maximum 200 Words)

TRAIL is a tumor necrosis factor family member that can specifically induce apoptosis of cancer cells but not of normal cells. However, some cancer cells are resistant to TRAIL-induced apoptosis. The purpose of this proposed study is to clone and characterize such inhibitory genes of TRAIL-induced apoptosis. Using cDNA subtraction and retroviral cDNA-based expression cloning approaches, we have obtained more than 50 candidate clones of TRAIL-inhibitory genes in the first year. In the second year, we have identified and validated Casper-S as a major cellular inhibitor of TRAIL-induced apoptosis. In the third year, we have further characterized the other candidate clones. The project has been approved for a one-year extension without additional funds.

14. SUBJECT TERMS Cancer Therapy, Apopto Hybridization, Signali	15. NUMBER OF PAGES 8 16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

Cover	.1
SF 298	.2
Table of Contents	.3
Introduction	.4
Body	.4
Key Research Accomplishments	.6
Reportable Outcomes	.6
Conclusions	6
References	6
Appendices	3

Reply to previous review

We thank the reviewer for his/her helpful comments on our original report. We have now modified the report as the reviewer suggested. In the revised progress report, we have added literature references; we have marked the report for unlimited distribution; we have provided a more comprehensive presentation of data. We hope the revised report is now satisfactory.

INTRODUCTION

TRAIL is a tumor necrosis factor family member that can specifically induce apoptosis of cancer cells but not of normal cells (1-5). However, some cancer cells are resistant to TRAIL-induced apoptosis (3, 4, 6-13). The purpose of this proposed study is to clone and characterize such inhibitory genes of TRAIL-induced apoptosis. To this end, following specific aims are proposed: #1. To clone genes that inhibit TRAIL-induced apoptosis of MCF7 cells by a subtractive hybridization screening approach and an expression/functional cloning approach using retroviral cDNA libraries; #2. To functionally characterize genes identified from specific aim #1.

BODY

We proposed the following Tasks and time frames in the original proposal:

- Task 1. To clone genes which inhibit TRAIL-induced apoptosis of MCF7 cells by a subtractive hybridization screening approach and an expression/functional cloning approach using retroviral cDNA libraries (months 1-24)
 - a. Isolate and amplify TRAIL resistant (MCF7-R) and sensitive (MCF7-S) MCF7 cells (months 1-2)
 - b. Identify genes that inhibit TRAIL-induced apoptosis of MCF7 cells by a subtractive hybridization screening approach (months 3-12)
 - c. Confirm that identified candidate genes are differentially expressed in MCF7-S and MCF-R cells Northern blot analysis (months 13-15)
 - d. Identify genes that inhibit TRAIL-induced apoptosis of MCF7 cells by an expression/functional cloning approach using retroviral cDNA libraries (months 3-20)
 - e. Clone full length cDNAs for genes that are identified from Task 1 (months 21-24)
- Task 2. To functionally characterize genes identified from Task 1 (months 25-36)
 - a. Determine tissue distribution of expression of the genes cloned in *Task 1* (months 25-26).
 - b. Test whether these genes can inhibit TRAIL-induced apoptosis of MCF7-S cells in apoptosis assays (months 25-28)

c. Determine the molecular mechanisms responsible for the inhibition of TRAIL-induced apoptosis of MCF7-S cells by the genes identified in *Task 1* (months 29-36)

In the first year, we successfully performed Task 1, a,b,and partially performed Task 1d. In the second year, we continued to perform Task 1d. We sequenced a total of 52 TRAIL resistant clones obtained from retroviral cDNA library based functional cloning approach. Very interestingly, among the 52 sequenced clones, 17 encode for Casper/c-FLIP. Further sequencing analysis suggests that all 17 Casper clones represent the short splice form of Casper (Casper-S). Because of this striking observation, we decided to slightly modify our original plans to finish this project. Rather than simultaneously cloning and functionally characterizing all the candidate genes obtained from the first year, we decided to focus on the short splice form of Casper first. Using transient transfection and stable transfection approaches, we firstly confirmed that Casper-S could confer resistance to TRAIL sensitive cells. Furthermore, we found that Casper deficient embryonic fibroblasts (EFs) were highly sensitive while their wild-type counterparts were completely resistant to TRAIL-induced apoptosis. Retroviral-mediated transduction of Casper-S into Casper(-/-) EFs restored resistance to TRAIL. These data suggest that Casper-S/c-FLIPs is a major cellular inhibitor of TRAIL-induced apoptosis. Our studies on Casper-S in TRAIL resistance have been published (14).

Our results on Casper-S indicated that our approaches for identification of TRAIL resistant genes worked properly, and we validated the first TRAIL resistant genes identified in this project. So, in the second year of this project, we finished Task 1a, 1b, 1d, and partially finished Task1c, 1e, and Task 2.

Work done in the third year

In the third year, we further analyzed the other candidate genes obtained from the expression cloning. We made retroviral expression plasmids for 12 candidate genes. To do this, we amplified cDNAs for these genes by PCR using a mixed cDNA libraries or the isolated clones as templates. The cDNAs were inserted into the pFB-Neo retroviral plasmid (Stratagene). The identities and related information are summarized in Table I.

Candidate genes Known functions Referen	
PP2Ac Protein phosphatase 15	
CL100/DUSP1 Dual specific phosphatase 16-17	
FIP-1/RagA Ras-related GTPase 18	
RAN Ras family member 19	
NALP1/CARD7 CARD domain-containing protein 20	
MKK4 MAP kinase kinase 21	
α1-antiproteinase Serine proteinase inhibitor 22	
NOS3 Nitric oxidase synthase 23	
SPTLC1 Serine palmitoyltransferase 24	
C10 Novel	
C11 Novel	
C13 Novel	

We transduced these genes into TRAIL sensitive cell clone C1 by retroviral-mediated gene transfer. Two days after infection with the retrovirus containing these genes, cells were treated with TRAIL for overnight. We used 200 ng/ml of TRAIL for the treatment, a concentration we used in the previous expression cloning. We found that retroviral mediated transfer of the tested genes did not confer resistance to TRAIL-induced apoptosis, as judged by observation under a microscope.

To exclude the possibility that the genes were not expressed or the efficiency of retroviral-mediated gene transfer was low in the experiments, we are making retroviral vectors in which a Flag epitope tag is added to the candidate proteins. We will transduce these vectors into C1 cells and establish stable cell lines by selection with G418. We will then detect the expression of the transduced proteins by Western blot analysis with anti-Flag antibody. If protein expression is detected, we will then evaluate whether the cells are resistant to TRAIL. If necessary, we will quantitate TRAIL-induced apoptosis by MTT assays.

KEY RESEARCH ACCOMPLISHMENTS

Cloned 12 candidate genes into retroviral vector and determined whether twelve of the candidate genes could inhibit TRAIL-induced apoptosis.

REPORTABLE OUTCOMES

None

CONCLUSIONS

In the third year of the proposed study, we have cloned 12 candidate genes into retroviral vector and determined whether they can inhibit TRAIL-induced apoptosis. Although no positive genes are identified, we have worked on this project as proposed. The project has been approved for one-year extension without additional funding. We hope to validate the other candidate genes in the coming year.

REFERENCES

- 1. Wiley, S.R., Chooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., Sutherland, G.R., Smith, T.D., Rauch, C., Smith, C.A., and Goodwin, R.G. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
- 2. Pitti, R.M., Marsters, S.A., Ruppert, S., Donahue, C.J., Moore, A., Ashkenazi, A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:12687-12690.
- 3. Degli-Esposti, M.A., Dougall, W.C., Smolak, P.J., Waugh, J.Y., Smith, C.A., Goodwin, R.G. 1997. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813-820.

- 4. Griffith, T.S., Chin, W.A., Jackson, G.C., Lynch, D.H., Kubin, M.Z. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:2833-2840.
- 5. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C., Lynch, D.H. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157-163.
- 6. Pan, G., Ni, J., Wei, Y.F., Yu, G.I., Gentz, R, Dixit, V.M. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-817.
- 7. Sheridan, J.P., Marsters, S.A., Pitti, P.M., Gurney, A., Skubatch, M., Baldwin, D., Ramkrishnan, I., Gray, C.L., Baker, K., Wood, W.I., Goddard, A.D., Godowski, P., Ashkenazi, A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821.
- 8. MacFarlane, M., Ahmad, M., Srinivasula, S.M., Fernades-Alnemri, T., Cohen, G.M., Alnemri, E.S. 1997. Identification and molecular cloning of two receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272:25417-25420.
- 9. Screaton, G.R., Mongkolsapaya, J., Xu, X.N., Cowper, A.E., McMichael, A.J., Bell, J.I. 1997. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:693-697.
- 10. Degli-Esposti, M.A., Smolak, A.J., Walczak, H., Waugh, J., Huang, C.P., DuBose, R.F., Goodwin, R.G., and Smith, C.A. 1997. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186:1165-1700.
- 11. Mongkolsapaya, J., Cowper, A.E., Xu, X.N., Morris, G., McMichael, A.J., Bell, J.I., Screaton, G.R. 1988. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new recetpor portecting lympohocytes from the death ligand TRAIL. J. Immunol. 160:3-7.
- 12. Marsters, S.A., Sheridan, J.P., Pitti, R.M., Huang, A, Skubatch, M., Baldwin, D., and et al. 1997. A novel receptor for Apo2/TRAIL contains a truncated death domain. Curr. Biol. 7:1003-1006.
- 13. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., DeForge, L., Koumenis, I.L., Lewis, I.L., Harris, D.L., Bussiere, J., Koeppen, H., Shahrokh, Z. and Schwall, R.H. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.
- 14. Bin, L., Li, X., Xu, L., Shu, H.B. 2002. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Letter 510:37-40.
- 15. Van Hoof, C., Goris, J. 2003. Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim Biophys Acta. 1640:97-104.
- 16. Alessi, D.R., Smythe, C., Keyse, S.M. 1993. The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts. Oncogene. 8:2015-2020.
- 17. Keyse, S.M., Emslie, E.A. 1992. Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 359:644-647.
- 18. Li, Y., Kang, J., Horwitz, M.S. 1997. Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers. J. Virol. 71:1576-1582.

- 19. Takai, Y., Sasaki, T., Matozaki, T. 2001. Small GTP-binding proteins. Physiol. Rev. 81:153-208.
- 20. Tschopp, J., Martinon, F., Burns, K. 2003. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 4:95-104.
- 21. Widmann, C., Gibson, S., Jarpe, M.B., Johnson, G.L. 1999. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79:143-180.
- 22. Goldsmith, E.J., Mottonen, J. 1994. Serpins: the uncut version. Structure. 2:241-244.
- 23. Lane, P., Gross, S.S. 1999. Cell signaling by nitric oxide. Semin. Nephrol. 19:215-229.
- 24. Hanada, K. 2003. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim. Biophys. Acta. 1632:16-30.

APPENDICES

None